奧昔嘌醇

奧昔嘌醇
	IUPAC名; 1H-pyrazolo[3,4-d]pyrimidine-4,6(2H,5H)-dione
別名	2,5-二氫-1H-吡唑並[3,4-d]嘧啶-4,6-二酮
識別
CAS號	2465-59-0
PubChem	4644
ChemSpider	4483
SMILES	O=C1NC(=O)C2=CNNC2=N1;
InChI	1S/C5H4N4O2/c10-4-2-1-6-9-3(2)7-5(11)8-4/h1H,(H3,6,7,8,9,10,11);
InChIKey	HXNFUBHNUDHIGC-UHFFFAOYSA-N
Beilstein	139956
EINECS	219-570-9
ChEBI	28315
KEGG	C07599
MeSH	Oxypurinol
性質
化學式	C5H4N4O2
莫耳質量	152.11086 g·mol⁻¹
外觀	白色晶體
	若非註明，所有數據均出自標準狀態（25 ℃，100 kPa）下。

奧昔嘌醇（INN：oxipurinol；USAN：oxypurinol）是黃嘌呤氧化酶的抑制劑。^[1]它是別嘌醇的活性代謝物，通過腎臟清除。^[2]在患有腎臟疾病的情況下，這種代謝物會積累到有毒水平。它通過抑制黃嘌呤氧化酶，從而減少尿酸的產生。高血清尿酸水平可能會導致痛風、腎結石和其他疾病。

參考資料[編輯]

^ Stocker, Sophie L; McLachlan, Andrew J; Savic, Radojka M; Kirkpatrick, Carl M; Graham, Garry G; Williams, Kenneth M; Day, Richard O. The pharmacokinetics of oxypurinol in people with gout. British Journal of Clinical Pharmacology. 2012, 74 (3): 477–489. PMC 3477349 . PMID 22300439. doi:10.1111/j.1365-2125.2012.04207.x.
^ Elion, Gertrude B; Yü, Ts'ai-Fan; Gutman, Alexander B; Hitchings, George H. Renal clearance of oxipurinol, the chief metabolite of allopurinol. The American Journal of Medicine. 1968, 45 (1): 69–77. PMID 5658870. doi:10.1016/0002-9343(68)90008-9.

[1] Stocker, Sophie L; McLachlan, Andrew J; Savic, Radojka M; Kirkpatrick, Carl M; Graham, Garry G; Williams, Kenneth M; Day, Richard O. The pharmacokinetics of oxypurinol in people with gout. British Journal of Clinical Pharmacology. 2012, 74 (3): 477–489. PMC 3477349 . PMID 22300439. doi:10.1111/j.1365-2125.2012.04207.x.

[2] Elion, Gertrude B; Yü, Ts'ai-Fan; Gutman, Alexander B; Hitchings, George H. Renal clearance of oxipurinol, the chief metabolite of allopurinol. The American Journal of Medicine. 1968, 45 (1): 69–77. PMID 5658870. doi:10.1016/0002-9343(68)90008-9.

[1]

[2]